Member access

4-Traders Homepage  >  Shares  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Roche Holding AG is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.As a large biotech company, Roche has truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.It is also a leader in in-vitro... 
Sector
Pharmaceuticals
Calendar
12/03Presentation
Surperformance© rating of Roche Holding Ltd.
Trading Rating : Investor Rating :
More about the company
Financials ( CHF)
Sales 2014 47 249 M
EBIT 2014 17 495 M
Net income 2014 11 781 M
Debt 2014 6 543 M
Yield 2014 2,85%
Sales 2015 49 645 M
EBIT 2015 18 837 M
Net income 2015 12 825 M
Debt 2015 650 M
Yield 2015 3,08%
PER 2014 20,76
PER 2015 18,85
EV / Sales 2014 5,38x
EV / Sales 2015 5,00x
Capitalization 247 549 M
More Financials
Latest news on ROCHE HOLDING LTD.
2d ago U.S. court denies Ranbaxy's bid to block launch of rival generics
4d ago Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies
5d ago Pfizer dampens Astra bid hopes with German Merck cancer deal
5d agoDJROCHE : Gets U.S. Approval for Avastin Treatment of Ovarian Cancer
11/14 ROCHE : FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy t..
10/27 Weak Merck sales overshadow third quarter cost cuts
10/22 Roche to spend $3.2 billion on towering Basel base
10/22DJRoche to Spend CHF3 Billion in Research Center, Basel Headquarters
10/16 ROCHE : Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® an..
10/16 New breast cancer drugs boost sales at Roche
10/15 ROCHE : FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulm..
10/13DJRoche Holding 3Q 2014 -- Forecast
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF